In the SOD1-G93A mouse model of ALS, AXX71 treatment resulted in a significant down-regulation of pro-inflammatory markers such as IL-1β, NOX2, and NF-κB in the spinal cord at the end of the disease. Here, SOD1 is linked to amyotrophic lateral sclerosis.